Shares of Embecta Corp. (NASDAQ:EMBC – Get Free Report) have received a consensus recommendation of “Strong Sell” from the five ratings firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $11.00.
Several brokerages have weighed in on EMBC. Bank of America reduced their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Weiss Ratings lowered Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, May 6th. Zacks Research cut Embecta from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Finally, Mizuho decreased their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th.
Check Out Our Latest Report on Embecta
Institutional Inflows and Outflows
Embecta Stock Performance
NASDAQ EMBC opened at $3.08 on Friday. The company has a market capitalization of $182.74 million, a PE ratio of 1.62 and a beta of 0.83. Embecta has a 52-week low of $2.77 and a 52-week high of $15.55. The company has a 50-day simple moving average of $5.88 and a 200 day simple moving average of $9.17.
Embecta (NASDAQ:EMBC – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The company had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. During the same period in the prior year, the company earned $0.70 earnings per share. The firm’s revenue was down 14.4% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, analysts forecast that Embecta will post 1.62 EPS for the current fiscal year.
Embecta Cuts Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Thursday, May 28th will be given a $0.01 dividend. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $0.04 annualized dividend and a dividend yield of 1.3%. Embecta’s payout ratio is 2.11%.
About Embecta
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Further Reading
- Five stocks we like better than Embecta
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
